This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
An affiliate of Paul Royalty Fund II will pay up to $61mm for a stake in Avant Immunotherapeutics' net royalties on worldwide sales of Rotarix, an oral rotavirus vaccine that Avant has licensed to GlaxoSmithKline; in most territories the royalty rate will range from 7-10%. Rotavirus is the main cause of acute pediatric diarrhea and dehydration and can be fatal.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?